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Abstract : We evaluated the effects of glucose metabolism and blood pressure
（BP） variability on cardiac diastolic function in patients with type 2 diabetes mel-
litus（T2DM） and hypertension.  A total of 23 inpatients with T2DM underwent 
ambulatory BP monitoring（ABPM） and echocardiography.  BP variability was 
assessed by measuring the mean BP and the standard deviation（SD） of systolic 
and diastolic BP over 24 hours, as well as daytime and nighttime ABPM.  Cardiac 
diastolic function was assessed using the echocardiography E/e′ ratio.  Participants 
had a mean age of 69.0±10.6 years, disease duration of 11.0±10.5 years, glycated 
hemoglobin（HbA1c） of 8.2％±1.3％, and glycated albumin（GA） of 22.0％±
4.2％.  Univariate analysis showed that the nighttime systolic BP, nighttime SDs of 
systolic and diastolic BP, urinary albumin, estimated glomerular ltration rate, and 
GA / HbA1c ratio were all signicantly correlated with the E/e′ ratio.  Moreover, 
stepwise multiple regression analysis identied nighttime SD of diastolic BP, urinary 
albumin, and GA / HbA1c ratio as independent contributors to the E/e′ ratio.  In 
patients with T2DM and hypertension, cardiac diastolic function was associated with 
nighttime diastolic BP variability and the GA / HbA1c ratio.
Key words : blood pressure variability, cardiac diastolic function, glycated albumin /
glycated hemoglobin ratio, ambulatory blood pressure monitoring, type 
2 diabetes mellitus
Introduction
　The coexistence of diabetes and hypertension is common and associated with an increased 
risk of death and cardiovascular events as well as the progression of microvascular complications, 
such as nephropathy and retinopathy1，2）.  Type 2 diabetes mellitus（T2DM） is also a major cause 
of heart failure, with reduced or preserved ejection fraction3）.  The Framingham Heart Study 
demonstrated that the frequency of heart failure is five times higher in women with diabetes 
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and two times greater in men with diabetes compared with age-matched controls4）.  It was 
recently reported that the most frequent heart alteration in T2DM is heart failure with preserved 
ejection fraction5）.  It was also reported that around 50％ of patients with hypertension suffer 
heart failure with preserved ejection fraction6）.
　The short and long-term variability of glucose and blood pressure（BP） levels have been studied. 
Recently, long-term variability in visit-to-visit glucose levels, as well as BP, was shown to be related 
to macrovascular and microvascular complications in patients with T2DM7，8）.  Advances in medical 
technology, such as continuous glucose monitoring（CGM） and 24-hr ambulatory BP monitoring
（ABPM）, have enabled short-term glucose and BP variability to be detected in greater detail. 
The mean amplitude of glycemic excursions（MAGE） is a short-term glucose variability 
index that has been associated with oxidative stress9）, vascular endothelial dysfunction10）, and 
narrowing of the coronary artery11）.  Nighttime BP variability, a short-term BP variability index, 
is also reported to be a strong predictor for cardiovascular disease in patients with T2DM 
and hypertension12）.  However, few studies have investigated the relationship between glucose 
variability, BP variability, and heart failure.
　Therefore, the present study aimed to determine whether glucose and BP variability, measured 
using the glycated albumin（GA）/ glycated hemoglobin（HbA1c） ratio and ABPM, respectively, 
are associated with the early diastolic（E）/ spectral pulsed-wave Doppler-derived lateral early 
diastolic velocity（e′） ratio, an index of heart failure with preserved ejection fraction in patients 
with T2DM and hypertension.
Patients and methods
　Participants
　This retrospective, observational study included 23 inpatients with T2DM and hypertension 
recruited from among patients treated at Showa University Hospital from May 2017 to October 
2018.  The patients were admitted to the hospital to achieve glycemic control due to poor 
current control.  The inclusion criteria were as follows: a diagnosis of T2DM and hypertension, 
age over 20 years, and stable diabetes and hypertension treatment for ≥ 3 months prior to the 
study.  T2DM was defined according to the Japan Diabetes Society.  Hypertension was defined 
as a systolic BP（SBP）≥140 mmHg and / or diastolic BP（DBP）≥ 90 mmHg on at least two 
occasions according to the current guidelines, or a previous diagnosis of hypertension and 
treatment with antihypertensive medication.  The exclusion criteria for patients were: 1） ejection 
fraction＜ 50％ ; 2） shift to a different medicine within the last month; 3） use of steroid anti-
inflammatory drugs ; 4） secondary diabetes ; 5） malignancy; 6） liver disease; 7） valvular heart 
disease ; 8） myocardial infarction with asynergy ; and 9） estimated glomerular filtration rate
（eGFR）＜ 30 ml/min/1.73 m2.
Study design
　Figure 1 shows a summary of the study protocol.  This was a retrospective observational 
analysis of patients with T2DM who underwent a 24-hr period of ABPM and echocardiography 
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monitoring.  Clinical and laboratory parameters, including body mass index（BMI）, fasting 
plasma glucose, HbA1c, GA, eGFR, low-density lipoprotein cholesterol, high-density lipoprotein 
cholesterol, and triglycerides were measured before breakfast on Day 2.  We used the GA /
HbA1c ratio as a marker of glucose variability.  Clinical data（age, sex, smoking status, duration 
of diabetes, diabetes therapy, and the use of antihypertensive and lipid-lowering drugs） were 
retrieved from medicals records.  Parameters of BP variability, such as mean and standard 
deviation（SD） of BP, and percentage coefficient of variation for BP（％CV） were measured 
for 24 hr, starting on Day 2.  All patients continued their usual treatment during ABPM. 
Echocardiography was performed on Day 3.  E/e′ was used as a parameter of cardiac diastolic 
function.  The study protocol was approved by the School of Medicine, Showa University Ethical 
Committee（Permit Number : 2465） and was designed in compliance with the Declaration of 
Helsinki.  Informed consent was obtained from all participants after receiving an explanation of 
the study protocol.
Procedures and measurements
　Venous blood samples were taken for laboratory analysis on Day 2 before breakfast.  All 
patients received a weight-maintaining diet（25-30 kcal/kg of ideal body weight） with salt 
restriction（＜6 g/day）.  After attaching the ABPM device（Mobil-O-graph; I.E.M. GmbH, Stolberg, 
Germany） on Day 2, BP was measured in the left upper extremity using the oscillometric method 
and pulse rate at 30 min intervals for 24 hr.  Daytime and nighttime were defined based on the 
patients’ written diaries recorded during ABPM.  BP variability was estimated using the SD of 
SBP and DBP during the daytime and nighttime.  The ％CV was calculated using the coefficient 
of variation obtained by dividing the SD by the mean BP and multiplying by 100.  Mean SBP 
and DBP during the daytime and nighttime were also determined.  
　Echocardiography was performed using commercially available ultrasound systems（iE33 ; 
Philips, Amsterdam, Netherlands ; Vivid E9 ; GE Healthcare UK, Ltd., Amersham, England, 
UK）.  Standard echocardiographic measurements were obtained in accordance with the current 
guidelines of the American Society of Echocardiography / European Association of Cardiovascular 
Imaging13）.  Specifically, the early diastolic（E） velocities and the E-wave deceleration time were 
measured using the pulsed-wave Doppler recording from the apical four chamber view.  Spectral 
Fig. 1.   Study protocol. Laboratory parameters were measured before breakfast 
on Day 2. Parameters of blood pressure variability were measured for 
24 hours, starting on Day 2. Echocardiography was performed on Day 3. 
ABPM, ambulatory blood pressure monitoring.
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pulsed-wave Doppler-derived lateral early diastolic velocity（e′） was considered as the lateral 
mitral annulus, and the E/e′ ratio was calculated to estimate the left ventricular filling pressure.
Laboratory measurements
　The serum total cholesterol, low-density lipoprotein cholesterol, high-density lipoprotein 
cholesterol, triglycerides and creatinine levels were measured using an automated analyzer
（BM6070 ; Japan Electron Optics Laboratory, Tokyo, Japan）.  Plasma glucose was measured 
using the glucose oxidase method, whereas HbA1c was measured using high-performance liquid 
chromatography14） while GA was detected using the bromocresol purple method.
Statistical analysis
　Data are expressed as mean ± SD.  Spearman’s rank correlation coefficient was used to 
determine univariate analysis.  Multiple stepwise regression analysis（forward–backward stepwise 
selection method） was used to assess independent contributors to the E/e′ ratio.  Analyses were 
performed using IBM SPSS, version 22, for Windows（IBM Corp; Armonk, NY, USA） with 
p-values＜ 0.05 indicating statistical significance.
Results
Clinical characteristics
　Table 1 shows the clinical and laboratory characteristics of the 23 participants.  Participants 
had a mean age of 69.0 ± 10.6 years, diabetes duration of 11.0 ± 10.5 years, and HbA1c level of 
8.2％± 1.3％.  The study group included more men（n＝14） than women（n＝9）, and participants 
were slightly overweight（BMI＝24.2 ± 4.7 kg/m2）.  The left ventricular ejection fraction was 
63.6％± 6.1％ and the E/e′ ratio was 7.1 ± 2.0.  At baseline, 56.5％ of the patients were on diet 
therapy, 39.1％ were taking angiotensin Ⅱ receptor blockers, 30.4％ were taking calcium channel 
blockers for hypertension treatment, 47.8％ were taking dipeptidyl peptidase 4 inhibitors, and 
43.5％ were on insulin therapy for diabetes treatment.
Table 1.  Baseline clinical characteristics of the study participants
Clinical characteristics Mean ± SD, n（％）
Age（years） 69.0 ± 10.6
Sex（male） 14（60.9）
Body mass index（kg/m2） 24.2 ± 4.7
Smoking  4（17.4）
Duration of diabetes（years） 11.0 ± 10.5
Dyslipidemia 22（95.7）
　Low-density lipoprotein cholesterol（mg/dl） 98.0 ± 30.5
　High-density lipoprotein cholesterol（mg/dl） 46.1 ± 13.1
　Triglycerides（mg/dl） 134.4 ± 60.3
Estimated glomerular ltration rate（ml/min/1.73 m2） 69.2 ± 19.7
Urinary albumin-to-creatinine ratio（mg/g） 68.3 ± 188.6
Fasting plasma glucose（mg/dl） 132.4 ± 30.8
HbA1c（％） 8.2 ± 1.3
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Clinical characteristics Mean ± SD, n（％）
1.5-anhydro-D-glucitol（µg/dl） 4.9 ± 8.2
GA（％） 22.0 ± 4.2
GA/HbA1c ratio 2.7 ± 0.4
Markers of BP variability
　24-hr mean SBP（mmHg） 124.5 ± 12.2
　24-hr SD of SBP（mmHg） 12.6 ± 3.6
　24-hr ％CV of SBP 10.0 ± 2.6
　24-hr mean DBP（mmHg） 77.0 ± 7.6
　24-hr SD of DBP（mmHg） 9.6 ± 2.4
　24-hr ％CV of DBP 12.6 ± 3.1
　Daytime mean SBP（mmHg） 125.5 ± 12.0
　Daytime SD of SBP（mmHg） 12.3 ± 3.9
　Daytime ％CV of SBP 9.7 ± 2.8
　Daytime mean DBP（mmHg） 78.1 ± 7.7
　Daytime SD of DBP（mmHg） 9.2 ± 2.6
　Daytime ％CV of DBP 11.8 ± 3.2
　Nighttime mean SBP（mmHg） 119.1 ± 16.2
　Nighttime SD of SBP（mmHg） 8.9 ± 4.3
　Nighttime ％CV of SBP 7.4 ± 3.2
　Nighttime mean DBP（mmHg） 72.0 ± 9.3
　Nighttime SD of DBP（mmHg） 7.8 ± 2.8
　Nighttime ％CV of DBP 11.1 ± 4.2
　24-hr pulse pressure（mmHg） 47.5 ± 9.0
　Daytime pulse pressure（mmHg） 47.3 ± 8.9
　Nighttime pulse pressure（mmHg） 47.1 ± 10.4
Ejection fraction（％） 63.6 ± 6.1
E/e′ 7.1 ± 2.0
Macroangiopathy  7（23.3）
Nephropathy  5（21.7）
Neuropathy 15（65.2）
Retinopathy  2（ 8.7）
Diabetes therapy
　Diet alone  3（13.0）
　Metformin  6（26.1）
　Sulfonylurea  4（17.4）
　Glinide  0（ 0.0）
　α-Glucosidase inhibitor  3（13.0）
　Thiazolidine  1（ 4.3）
　Dipeptidyl peptidase 4 inhibitor 11（47.8）
　Sodium glucose cotransporter 2 inhibitors  5（21.7）
　Glucose-like peptide 1 receptor agonist  0（ 0.0）
　Insulin 12（52.2）
Antihypertensive drugs
　Diet alone 13（56.5）
　AngiotensinⅡ receptor blocker  9（39.1）
　Calcium channel blocker  7（30.4）
　Diuretic  1（ 4.3）
　α-blocker  0（ 0.0）
　β-blocker  3（12.0）
　Other treatments  0（ 0.0）
　Lipid-lowering drugs（statins） 13（56.5）
Data represent mean ± SD, or n（％）. SD, standard deviation; HbA1c, glycated hemoglobin; GA, 
glycated albumin; BP, blood pressure; SBP, systolic blood pressure; DBP, diastolic blood pressure; 
％CV, percentage coefcient of variation; E/e′, early diastolic transmitral inow velocity/lateral early 
diastolic mitral annular velocity.
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Relationship between E/e′ ratio, E, and e′ and markers of BP variability glucose metabolism, and 
non-glycemic clinical and laboratory variables
　Table 2 shows the correlations between the E/e′ ratio, E, and e′ and the markers of BP 
variability, glucose metabolism, and non-glycemic clinical and laboratory variables.  Significant 
correlations were observed between the E/e′ ratio and ejection fraction（ p＝0.047）, nighttime 
mean SBP（ p＝0.031）, nighttime SD of SBP（ p＝0.019）, nighttime SD of DBP（ p＝0.023）, 
Table 2.   Correlations between E/e′, E, and e′ and markers of BP control, glycemic con-
trol, and non-glycemic metabolic variables
Variable r
E/e′ E e′
Age（years） 0.360 -0.091 -0.594＊＊
Body mass index（kg/m2） -0.261 0.096 0.473＊
Duration of diabetes（years） 0.255 0.203 -0.089
Fasting plasma glucose（mg/dl） -0.039 -0.065 0.055
HbA1c（％） -0.298 -0.233 -0.099
1.5-anhydro-D-glucitol（µg/dl） 0.148 0.029 -0.195
GA（％） 0.156 -0.013 -0.376
GA / HbA1c ratio 0.550＊＊ 0.140 -0.476＊
Markers of BP variability
　24-hr mean SBP（mmHg） 0.257 0.203 -0.191
　24-hr SD of SBP（mmHg） 0.041 -0.184 -0.458＊
　24-hr ％CV of SBP -0.114 -0.281 -0.392
　24-hr mean DBP（mmHg） -0.168 0.216 0.105
　24-hr SD of DBP（mmHg） -0.024 -0.102 -0.272
　24-hr ％CV of DBP -0.048 -0.143 -0.249
　Daytime mean SBP（mmHg） 0.230 0.197 -0.173
　Daytime SD of SBP（mmHg） 0.094 -0.343 -0.600＊＊
　Daytime ％CV of SBP -0.029 -0.445＊ -0.639＊＊
　Daytime mean DBP（mmHg） -0.245 0.138 0.121
　Daytime SD of DBP（mmHg） 0.001 -0.120 -0.357
　Daytime ％CV of DBP -0.010 -0.176 -0.393
　Nighttime mean SBP（mmHg） 0.450＊ 0.150 -0.385
　Nighttime SD of SBP（mmHg） 0.484＊ 0.183 -0.159
　Nighttime ％CV of SBP 0.266 0.177 0.055
　Nighttime mean DBP（mmHg） 0.307 0.032 -0.302
　Nighttime SD of DBP（mmHg） 0.473＊ 0.084 -0.237
　Nighttime ％CV of DBP 0.250 0.081 -0.020
　24-hr pulse pressure（mmHg） 0.492＊ 0.117 -0.430＊
　Daytime pulse pressure（mmHg） 0.463＊ 0.112 -0.405
　Nighttime pulse pressure（mmHg） 0.529＊＊ 0.099 -0.441＊
Low-density lipoprotein cholesterol（mg/dl） 0.126 0.073 -0.045
High-density lipoprotein cholesterol（mg/dl） -0.359 -0.153 0.173
Triglycerides（mg/dl） -0.278 0.064 0.135
Estimated GFR（ml/min/1.73 m2） -0.425＊ -0.040 0.236
Urinary albumin-to-creatinine ratio（mg/g） 0.438＊ 0.359 -0.043
Ejection fraction（％） -0.418＊ -0.123 0.100
＊p＜ 0.05, ＊＊p＜ 0.01. BP, blood pressure; E, early diastolic transmitral inow velocity; e′, 
lateral early diastolic mitral annular velocity; HbA1c, glycated hemoglobin; GA, glycated 
albumin; SBP, systolic blood pressure; SD, standard deviation; ％CV, percentage coefcient 
of variation; DBP, diastolic blood pressure; GFR, glomerular ltration rate.
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GA/HbA1c ratio（ p＝0.007）, 24-hr pulse pressure（ p＝0.017）, daytime pulse pressure（ p＝0.026）, 
nighttime pulse pressure（ p＝0.009）, urinary albumin-to-creatinine ratio（ p＝0.037）, and eGFR
（ p＝0.043）.  However, no significant correlation was observed between the E/e′ ratio and fasting 
plasma glucose, HbA1c, and non-glycemic variables.
　E/e′ showed a positive correlation with the GA / HbA1c ratio, as depicted in Table 2.  In 
addition, the E/e′ ratio in patients with a GA / HbA1c ratio ≥ 2.8 was more than that in patients 
with a GA / HbA1c ratio＜ 2.8（Fig. 2）.
　Significant correlations were also observed between E and daytime ％CV of SBP（ p＝0.034）, 
and between e′ and 24-hr SD of SBP（ p＝0.032）, daytime SD of SBP（ p＝0.003）, daytime ％
CV of SBP（ p＝0.001）, 24-hr pulse pressure（ p＝0.046）, nighttime pulse pressure（ p＝0.040）, 
age（ p＝0.004）, BMI（ p＝0.026）, and GA / HbA1c ratio（ p＝0.025; Table 2）.
　Multivariate analysis identified the GA / HbA1c ratio, urinary albumin-to-creatinine ratio, and 
nighttime SD of DBP as independent and significant determinants of the E/e′ ratio（adjusted 
multiple R2＝ 0.526; Table 3）.
Fig. 2.   E/e′ ratio in patients with GA / HbA1c ratio ≥ 2.8 or＜ 2.8. 
E/e′, early diastolic transmitral inflow velocity / lateral early 
diastolic mitral annular velocity; GA, glycated albumin; HbA1c, 
glycated hemoglobin.
Table 3.  Linear multivariate analyses with E/e′ as dependent variable
Dependent variable: E/e′
β Coefcient t-value p-value Full-model R2
＜ 0.001 0.526
GA / HbA1c ratio 0.519 3.525 0.002
Urinary albumin-to-creatinine ratio 0.398 2.708 0.014
Nighttime SD of DBP 0.332 2.252 0.036
E/e′, early diastolic transmitral inflow velocity / lateral early diastolic mitral annular velocity ; GA, 
glycated albumin; HbA1c, glycated hemoglobin; SD, standard deviation; DBP, diastolic blood pressure.
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Discussion
　To the best of our knowledge, no previous studies have investigated the relationship between 
cardiac diastolic function, glucose, and BP variability in patients with T2DM with hypertension. 
Our findings are pertinent to the clinical management of T2DM with hypertension and highlight 
the importance of GA and BP variability, in addition to glucose and BP levels.
　Hypertension induces endothelial dysfunction via oxidative stress15）.  In cardiomyocytes, 
hypertension-induced oxidative stress causes S-glutathionylation of the myofibrillar protein, 
cardiac myosin binding protein C, leading to diastolic dysfunction16）.  Previous studies have 
reported that T2DM and hypertension are closely associated with heart failure with preserved 
ejection fraction17，18）.  T2DM and hypertension increases oxidative stress in the heart and blood 
vessels and leads to vascular endothelial dysfunction, left ventricular hypertrophy, and interstitial 
fibrosis19）.  The extent of microalbuminuria is correlated with the level of endothelial cell injury; 
hence, the urinary albumin-to-creatinine ratio is thought to be correlated with the E/e′ ratio. 
Therefore, it is speculated that increased oxidative stress ultimately leads to the onset of cardiac 
diastolic dysfunction.
　Postprandial plasma glucose is reported to be more closely related to cardiovascular disease 
than fasting plasma glucose.  Furthermore, glucose variability is important in patients with 
T2DM11） as it induces endothelial dysfunction via oxidative stress, as well as the progression of 
arteriosclerosis that causes cardiovascular disease20）.  In clinical studies, MAGE calculated using 
CGM is used as a glucose variability index.  Indeed, we previously reported a relationship 
between MAGE and oxidative stress9）.  Recently, the GA/HbA1c ratio has been shown to be a 
reliable marker of glucose variability, regardless of the degree of glycemic control21）.  Albumin is 
glycosylated much more easily than hemoglobin22）, and as blood glucose levels increase, the GA/
HbA1c ratio also increases.  Furthermore, patients with a GA/HbA1c ratio ≥ 2.8 show the highest 
SD23）.  Our study demonstrated that E/e′ is associated with the GA/HbA1c ratio; furthermore, 
patients with a GA/HbA1c ratio ≥ 2.8 had a high E/e′ ratio.  Therefore, we propose that 
chronic hyperglycemia is not the cause, but that glucose variability leads to oxidative stress and, 
ultimately, cardiac dysfunction.
　Studies have reported a relationship between cardiovascular disease and BP variability 
evaluated via ABPM.  Accordingly, several studies have demonstrated that nighttime SBP 
variability is a risk factor for cardiovascular disease24）.  However, the present study showed that 
nighttime DBP variability was associated with cardiac function.  This mechanism is unknown, but 
could be explained by the following pathophysiological mechanism.  Low DBP may compromise 
blood ow to target organs and impair coronary perfusion, causing cardiac ischemia25）.  Therefore, 
a large DBP variability is considered to be related to cardiac function due to the impairment of 
coronary perfusion.
　The present study has several limitations.  First, this was a cross-sectional study, precluding the 
evaluation of any cause and effect relationship between glucose and BP variability and cardiac 
diastolic function.  Further studies are necessary to examine whether interventions to reduce 
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glucose and BP variability are required.  Second, we did not evaluate the relationship between 
cardiac diastolic function and oxidative stress.  Third, the sample size was relatively small and 
any subgroup comparison may lack statistical power.  Significant correlations were observed 
between E/e′ and nighttime mean SBP, nighttime SD of SBP, and nighttime SD of DBP. 
Conversely, significant correlations were observed between e′ and 24-hr SD of SBP and daytime 
SD of SBP.  The reason that the result differs between E/e′ and e′ may be because e′ is 
influenced by age.  However, because the sample size is small, we found it difficult to study this 
in detail.  Fourth, we were unable to use CGM to evaluate glucose variability.  Fifth, since the 
glycemic control of the patients was poor, hyperglycemia and glucose variability may have had 
a significant effect on the results of our study.  Future studies are necessary to examine patients 
with good glycemic control.  Sixth, sleep apnea, which causes sympathetic activation, may have 
been a factor in the present study.  Seventh, few patients had poorly controlled hypertension in 
the study.  Therefore, it is difficult to compare patients with poorly controlled hypertension with 
patients with well-controlled hypertension.  Eighth, there was no patient with an E/e′ ratio＞ 14, 
which is the cut-off level of E/e′ for diastolic dysfunction, according to the Japanese guidelines 
for Diagnosis and Treatment of Acute and Chronic Heart Failure.  Finally, it has been reported 
that ％CV of BP is useful as a BP variability index26）.  However, there was no significant 
relationship between ％CV of BP and E/e′.  Hence, the relationship between the SD of BP and 
E/e′ is likely important, but the SD of BP positively correlates with the mean BP.  In the future, 
it will be necessary to investigate an increased number of cases with these relationships in order 
to draw a firm conclusion.
　In conclusion, the present study demonstrates that cardiac diastolic function is associated with 
the GA/HbA1c ratio and nighttime DBP variability in patients with T2DM and hypertension. 
While further intervention studies are required to determine whether reducing glucose variability 
as well as BP variability is associated with improved cardiac diastolic function, our results imply 
that glucose and BP variability are important factors affecting cardiac diastolic function.
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